L3VLUP
ProSign in

WAT · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

WATJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • WAT
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterWATJNJ
Q3 202022 holders, $1.9bn30 holders, $26.2bn
Q4 202017 holders, $2.1bn32 holders, $26.6bn
Q1 202115 holders, $2.2bn31 holders, $25.3bn
Q2 202116 holders, $2.5bn37 holders, $25.6bn
Q3 202118 holders, $2.8bn40 holders, $24.1bn
Q4 202114 holders, $3.1bn33 holders, $25.2bn
Q1 202217 holders, $2.4bn35 holders, $28.2bn
Q2 202218 holders, $2.7bn33 holders, $26.9bn
Q3 202219 holders, $2.2bn36 holders, $25.4bn
Q4 202221 holders, $2.5bn35 holders, $27.6bn
Q1 202323 holders, $2.5bn42 holders, $24.5bn
Q2 202315 holders, $2.3bn38 holders, $25.0bn
Q3 202314 holders, $2.4bn37 holders, $18.9bn
Q4 20238 holders, $2.6bn31 holders, $19.0bn
Q1 20248 holders, $2.8bn32 holders, $19.7bn
Q2 202410 holders, $2.1bn35 holders, $20.4bn
Q3 20247 holders, $2.5bn28 holders, $22.3bn
Q4 202410 holders, $2.8bn37 holders, $20.4bn
Q1 202511 holders, $3.1bn32 holders, $20.5bn
Q2 202512 holders, $3.3bn31 holders, $18.4bn
Q3 202512 holders, $2.6bn32 holders, $23.7bn
Q4 202515 holders, $3.9bn29 holders, $27.8bn
Q1 202618 holders, $6.6bn34 holders, $35.6bn
Q2 202620 holders, $9.8bn33 holders, $39.1bn
WAT

Waters Corp

Holders
18
Reported value
$6.6bn
Buyers
27
Sellers
9

Breadth +18 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only WAT (7)

Artisan Partners LP, First Eagle Investment Management LLC, Harris Associates LP, Holocene Advisors LP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Viking Global Investors LP

Only JNJ (23)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Man Group PLC, Markel Group Inc, Millennium Management LLC, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Walleye Capital LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →